OpenNashEarnings

Pharmaceuticals · NYSE: BMY

Bristol Myers Squibb earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 4 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Third quarter revenues increased 7% to $13.1 billion; GAAP EPS was $1.05 and non-GAAP EPS was $1.35, and 2026 revenue guidance was raised to a range of $49.75 billion to $50.25 billion.

Bristol Myers Squibb's third-quarter revenue rose 7% to $13.1 billion. The Growth Portfolio of newer medicines increased 12% to $7.7 billion. The older Legacy Portfolio grew 1%, as Eliquis offset generic losses on other drugs. Non-GAAP EPS fell to $1.35 from $1.63 because Acquired IPRD charges and licensing income cost $(0.58) per share. Non-GAAP gross margin slipped to 68.4%, mainly on product mix.

Read the Q3 2026 summary →

Quarters

KPI history

Revenue$13.1B+6.9% y/yQ3 2026
Q4 2024: $12.3B (worked out from the annual figure)Q4 ’24$12.3BQ1 2025: $11.2BQ1 ’25$11.2BQ2 2025: $12.3BQ2 ’25$12.3BQ3 2025: $12.2BQ3 ’25$12.2BQ4 2025: $12.5B (worked out from the annual figure)Q4 ’25$12.5BQ1 2026: $11.5BQ1 ’26$11.5BQ2 2026: $13.0BQ2 ’26$13.0BQ3 2026: $13.1BQ3 ’26$13.1B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$12.3B *
Q1 2025$11.2B
Q2 2025$12.3B
Q3 2025$12.2B
Q4 2025$12.5B *
Q1 2026$11.5B
Q2 2026$13.0B
Q3 2026$13.1B
Diluted EPS (GAAP)$1.05−2.8% y/yQ3 2026
Q1 2025: $1.20Q1 ’25$1.20Q2 2025: $0.64Q2 ’25$0.64Q3 2025: $1.08Q3 ’25$1.08Q1 2026: $1.31Q1 ’26$1.31Q2 2026: $1.62Q2 ’26$1.62Q3 2026: $1.05Q3 ’26$1.05
Data
Q1 2025$1.20
Q2 2025$0.64
Q3 2025$1.08
Q1 2026$1.31
Q2 2026$1.62
Q3 2026$1.05

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Free cash flow$3.8B−36.0% y/yQ3 2026
Q4 2024: $4.1BQ4 ’24$4.1BQ1 2025: $1.7BQ1 ’25$1.7BQ2 2025: $3.6BQ2 ’25$3.6BQ3 2025: $6.0BQ3 ’25$6.0BQ4 2025: $1.6BQ4 ’25$1.6BQ1 2026: $757.0MQ1 ’26$757.0MQ2 2026: $3.1BQ2 ’26$3.1BQ3 2026: $3.8BQ3 ’26$3.8B
Data
Q4 2024$4.1B
Q1 2025$1.7B
Q2 2025$3.6B
Q3 2025$6.0B
Q4 2025$1.6B
Q1 2026$757.0M
Q2 2026$3.1B
Q3 2026$3.8B

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$12.3Bd$11.2B$12.3B$12.2B$12.5Bd$11.5B$13.0B$13.1B
Net income$72.0Md$2.5B$1.3B$2.2B$1.1Bd$2.7B$3.3B$2.2B
Diluted EPS—$1.20$0.64$1.08—$1.31$1.62$1.05
Operating cash flow$4.4Bd$2.0B$3.9Bd$6.3Bd$2.0Bd$1.1B$3.4Bd$4.2Bd
Capital expenditure$378.0Md$260.0M$361.0Md$320.0Md$370.0Md$347.0M$305.0Md$344.0Md
Free cash flow$4.1B$1.7B$3.6B$6.0B$1.6B$757.0M$3.1B$3.8B
R&D expense$3.2Bd$2.3B$2.6B$2.5B$2.6Bd$2.6B$3.0B$2.4B

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-Q and 10-K filings